Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation Authors
First Online: 26 March 2008 Received: 15 February 2008 Accepted: 19 February 2008 DOI:
Cite this article as: Bastepe, M. & Jüppner, H. Rev Endocr Metab Disord (2008) 9: 171. doi:10.1007/s11154-008-9075-3 Abstract
Phosphorous is essential for multiple cellular functions and constitutes an important mineral in bone. Hypophosphatemia in children leads to rickets resulting in abnormal growth and often skeletal deformities. Among various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Recent genetic analyses and subsequent biochemical and animal studies have revealed several novel molecules that appear to play key roles in the regulation of renal phosphate handling. These include a protein with abundant expression in bone, fibroblast growth factor 23 (FGF23), which has proven to be a circulating hormone that inhibits tubular reabsorption of phosphate in the kidney. Two other bone-specific proteins, PHEX and dentin matrix protein 1 (DMP1), appear to be necessary for limiting the expression of fibroblast growth factor 23, thereby allowing sufficient renal conservation of phosphate. This review focuses on the clinical, biochemical, and genetic features of inherited hypophosphatemic disorders, and presents the current understanding of hormonal and molecular mechanisms that govern phosphorous homeostasis.
Keywords Hypophosphatemic disorders Phosphorus Vitamin D PTH FGF23 PHEX DMP1 References
Miller WL, Portale AA. Genetic causes of rickets. Curr Opin Pediatr. 1999;11:333–9.
Demay MB, Sabbagh Y, Carpenter TO. Calcium and vitamin D: what is known about the effects on growing bone. Pediatrics. 2007;119 Suppl 2:S141–4.
Jüppner H, Thakker R. Genetic disorders of calcium and phosphate homeostasis. In: Pollak M (ed) The kidney. W.B. Saunders Company, Philadelphia, PA; 2008. (in press).
Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A. 2005;102:9637–42.
Forster IC, Hernando N, Biber J, Murer H. Proximal tubular handling of phosphate: a molecular perspective. Kidney Int. 2006;70:1548–59.
Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol. 2007;103:572–7.
Miyamoto K, Ito M, Tatsumi S, Kuwahata M, Segawa H. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol. 2007;27:503–15.
St-Arnaud R, Demay MB. Vitamin D biology. In: Glorieux FH, Juppner H, Pettifor JM, editors. Pediatric bone: biology and diseases. San Diego: Academic; 2003. p. 193–216.
Jüppner H, Gardella T, Brown E, Kronenberg H, Potts J Jr. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In: DeGroot L, Jameson J, editors. Endocrinology. 5th ed. Philadelphia, PA: W.B. Saunders Company; 2005. p. 1377–417.
Mensenkamp AR, Hoenderop JG, Bindels RJ. TRPV5, the gateway to Ca2+ homeostasis. Handb Exp Pharmacol. 2007;179:207–20.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
Portale AA, Miller WL. Rickets due to hereditary abnormalities of vitamin D synthesis and action. In: Glorieux FH, Juppner H, Pettifor JM, editors. Pediatric bone: biology and diseases. San Diego: Academic; 2003. p. 583–602.
Holm IA, Econs MJ, Carpenter TO. Familial hypophosphatemia and related disorders. In: Glorieux FH, Juppner H, Pettifor JM, editors. Pediatric bone: biology and diseases. San Diego, CA: Academic; 2003. p. 603–31.
White K, Larsson T, Econs M. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frp-4, MEPE, and FGF23. Endocr Rev. 2006;27 3:221–41.
Econs M, Drezner M. Tumor-induced osteomalacia—unveiling a new hormone. N Engl J Med. 1994;330:1679–81.
ADHR Consortium T; White KE, Evans WE, O’Riordan JLH, Speer MC, Econs MJ, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345–8.
Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser. 1971;7:287–95.
Econs M, McEnery P. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82:674–81.
Econs M, McEnery P, Lennon F, Speer M. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest. 1997;100:2653–7.
Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Mineral Res. 2007;22(4):520–6 (Apr).
Kruse K, Woelfel D, Strom T. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res. 2001;55:305–8.
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–8.
Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–32.
Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38–49.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500–5.
Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia
. Endocrinology. 2002;143:3179–82.
Benet-Pages A, Lorenz-Depiereux B, Zischka H, White K, Econs M, Strom T. FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004;35:455–62.
Berndt TJ, Craig TA, McCormick DJ, Lanske B, Sitara D, Razzaque MS, et al. Biological activity of FGF-23 fragments. Pflugers Arch. 2007;454:615–23.
Jan De Beur S, Finnegan R, Vassiliadis J, Cook B, Barberio D, Estes S, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res. 2002;17:1102–10.
White K, Jonsson K, Carn G, Hampson G, Spector T, Mannstadt M, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86:497–500.
Topaz O, Shurman D, Bergman R, Indelman M, Ratajczak P, Mizrachi M, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36:579–81.
Ichikawa S, Lyles K, Econs M. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab. 2005;90:2420–3.
Perwad F, Azam N, Zhang M, Yamashita T, Tenenhouse H, Portale A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358–64.
Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism
and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression
. Am J Physiol Renal Physiol. 2007;293:F1577–83.
Ferrari S, Bonjour J, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519–24.
Burnett S, Gunawardene S, Bringhurst F, Jüppner H, Lee H, Finkelstein J. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21:1187–96.
Consortium TH. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11:130–6.
Holm IA, Huang X, Kunkel LM. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet. 1997;60:790–7.
Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957–60.
Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New Engl J Med. 2003;348:1656–62.
Weber T, Liu S, Indridason O, Quarles L. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003;18:1227–34.
Aono Y, Shimada T, Yamazaki Y, Hino R, Takeuchi M, Fujita T, et al. The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice. Meeting of the American Society for Bone and Mineral Research, Minneapolis, Minnesota, 2003; p 1056.
Liu S, Brown T, Zhou J, Xiao Z, Awad H, Guilak F, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol. 2005;16:91645–53.
Bowe A, Finnegan R, Jan de Beur S, Cho J, Levine M, Kumar R, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001;284:977–81.
Perry W, Stamp T. Hereditary hypophosphataemic rickets with autosomal recessive inheritance and severe osteosclerosis. A report of two cases. J Bone Joint Surg Br. 1978;60-B:430–4.
Scriver C, Reade T, Halal F, Costa T, Cole D. Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child. 1981;56:203–7.
Bastepe M, Shlossberg H, Murdock H, Jüppner H, Rittmaster R. A Lebanese family with osteosclerosis and hypophosphatemia. J Bone Miner Res. 1999;14:S558.
Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248–50.
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–5.
George A, Sabsay B, Simonian PA, Veis A. Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J Biol Chem. 1993;268:12624–30.
Narayanan K, Ramachandran A, Hao J, He G, Park KW, Cho M, et al. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem. 2003;278:17500–8.
George A, Ramachandran A, Albazzaz M, Ravindran S. DMP1—a key regulator in mineralized matrix formation. J Musculoskelet Neuronal Interact. 2007;7:308.
Lu Y, Liu S, Yu S, Xie Y, Zhou J, Quarles L, et al. The 57 kDa C-terminal fragment of Dentin Matrix Protein 1 (DMP1) retains all biological activity: Osteocytic regulation of Pi homeostasis through FGF23. 29. Annual Meeting of American Society Bone and Mineral Research, Honolulu, Hawai, 2007.
Ye L, Mishina Y, Chen D, Huang H, Dallas S, Dallas M, et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem. 2005;280:6197–203.
Feng JQ, Scott G, Guo D, Jiang B, Harris M, Ward T, et al. Generation of a conditional null allele for Dmp1 in mouse. Genesis. 2008;46:87–91.
Lu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF, Feng JQ. DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res. 2007;86:320–5.
Beighton P. Osteoglophonic dysplasia. J Med Genet. 1989;26:572–6.
Beighton P, Cremin BJ, Kozlowski K. Osteoglophonic dwarfism. Pediatr Radiol. 1980;10:46–50.
White K, Cabral J, Evans W, Ichikawa S, Davis S, Ornitz D, et al. A missense mutation in FGFR1 causes a novel syndrome: craniofacial dysplasia with hypophosphatemia (CFDH). J Bone Miner Res. 2003;18 Suppl 2:S4.
Farrow E, Davis S, Mooney S, Beighton P, Mascarenhas L, Gutierrez Y, et al. Extended mutational analyses of FGFR1 in osteoglophonic dysplasia. Am J Med Genet. 2006;140:537–9.
Muenke M, Schell U, Hehr A, Robin NH, Losken HW, Schinzel A, et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet. 1994;8:269–74.
Roscioli T, Flanagan S, Kumar P, Masel J, Gattas M, Hyland VJ, et al. Clinical findings in a patient with FGFR1 P252R mutation and comparison with the literature. Am J Med Genet. 2000;93:22–8.
Hoffman W, Jüppner H, Deyoung B, O’dorisio M, Given K. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A. 2005;134:233–6.
Heike C, Cunningham M, Steiner R, Wenkert D, Hornung R, Gruss J, et al. Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis? Am J Med Genet A. 2005;139:67–77.
Weinstein L, Yu S, Warner D, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22:675–705.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. New Engl J Med. 1991;325:1688–95.
Schwindinger W, Francomano C, Levine M. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune–Albright syndrome. Proc Natl Acad Sci U S A. 1992;89:5152–6.
Riminucci M, Collins M, Fedarko N, Cherman N, Corsi A, White K, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683–92.
Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006;78:2295–301.
Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune–Albright syndrome. J Bone Miner Metab. 2005;23:231–7.
Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Ntp2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A. 1998;95:5372–7.
Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med. 1985;312:611–7.
Tieder M, Modai D, Shaked U, Samuel R, Arie R, Halabe A, et al. “Idiopathic” hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med. 1987;316:125–9.
Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium/phosphate cotransporter gene SLC34A3. Am J Human Genet. 2006;78 2:193–201.
Yamamoto T, Michigami T, Aranami F, Segawa H, Yoh K, Nakajima S, et al. Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function. J Bone Miner Metab. 2007;25:407–13.
Jones A, Tzenova J, Frappier D, Crumley M, Roslin N, Kos C, et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol. 2001;12:507–14.
Bergwitz C, Roslin N, Tieder M, Loredo-Osti J, Bastepe M, Abu-Zahra H, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) predict a key role for the sodium-phosphate co-transporter NaPi-IIc in maintaining phosphate homeostasis and skeletal function. Am J Human Genet. 2006;78 2:179–92.
Ichikawa S, Sorenson AH, Imel EA, Friedman NE, Gertner JM, Econs MJ. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab. 2006;91:4022–7.
Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med. 2002;347:983–91.
Virkki L, Forster I, Hernando N, Biber J, Murer H. Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa. J Bone Miner Res. 2003;18:2135–41.
Lapointe JY, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V, et al. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int. 2006;69:2261–7.
Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309–10.
Yamashita T, Konishi M, Miyake A, Inui K, Itoh N. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2002;277:28265–70.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–4.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120–3.
Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007;117:2684–91.
Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, et al. Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys. Biochem Biophys Res Commun. 2000;267:597–602.
Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004;29:91–9.
Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal–gastrointestinal–skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289:G1036–42.
Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest. 2006;116:3150–9.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro OM, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003–8.
Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125–31.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.
Nabeshima Y. Klotho: a fundamental regulator of aging. Ageing Res Rev. 2002;1:627–38.
Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–8.
PubMed CrossRef Copyright information
© Springer Science+Business Media, LLC 2008